Table 3.
Summary of grade 3 or higher neurologic toxicities
| Early (<6 months post-chemoradiation) | |||||
|---|---|---|---|---|---|
| Patient | MGMT* methylation status | Type | Grade | Interval from RT† (months) | Treatment |
| 1 | Negative | Seizure, worsened hemiparesis, imbalance | 3 | 0.6 | Steroids |
| 2 | Positive | Worsened gait, sensory neglect | 3 | 3 | Steroids, bevacizumab |
| 3 | Negative | Worsened hemiparesis and gait | 3 | 3 | Steroids, bevacizumab |
| 4 | Positive | Seizure, aphasia, worsened hemiparesis | 4 | During RT | Steroids, debulking surgery |
| Late (>6 months post-chemoradiation) | |||||
| 5 | Negative | Seizures | 3 | 10 | Bevacizumab |
| 6 | Positive | Hemiparesis, worsened gait and word-finding difficulty | 3 | 17 | Bevacizumab |
MGMT = O6-methylguanine-DNA methyltransferase;
RT=radiation therapy